Eikon Therapeutics (NASDAQ:EIKN) Major Shareholder Group Iv Gp Lp Column Acquires 89,200 Shares

Eikon Therapeutics, Inc. (NASDAQ:EIKN) major shareholder Group Iv Gp Lp Column acquired 89,200 shares of Eikon Therapeutics stock in a transaction on Thursday, September 3rd. The stock was acquired at an average cost of $11.56 per share, for a total transaction of $1,031,152.00. Following the purchase, the insider owned 89,200 shares of the company’s stock, valued at approximately $1,031,152. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Eikon Therapeutics Stock Performance

Shares of EIKN stock opened at $10.71 on Wednesday. Eikon Therapeutics, Inc. has a 52 week low of $7.90 and a 52 week high of $17.40. The stock has a market capitalization of $580.16 million and a PE ratio of -2.62. The stock’s fifty day moving average is $10.55 and its 200-day moving average is $10.88.

Eikon Therapeutics (NASDAQ:EIKN) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.61) by ($0.02). As a group, analysts forecast that Eikon Therapeutics, Inc. will post -7.24 earnings per share for the current fiscal year.

Institutional Trading of Eikon Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc acquired a new position in Eikon Therapeutics during the 2nd quarter valued at about $28,000. California State Teachers Retirement System acquired a new stake in shares of Eikon Therapeutics during the 2nd quarter worth approximately $51,000. The Manufacturers Life Insurance Company grew its position in shares of Eikon Therapeutics by 23.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 35,357 shares of the company’s stock worth $461,000 after buying an additional 6,734 shares during the period. Citadel Advisors LLC bought a new stake in shares of Eikon Therapeutics during the second quarter worth approximately $170,000. Finally, Deutsche Bank AG bought a new stake in shares of Eikon Therapeutics during the second quarter worth approximately $281,000.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on EIKN. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. Weiss Ratings raised shares of Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. Finally, Wedbush dropped their price objective on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a research report on Friday, August 14th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Eikon Therapeutics presently has an average rating of “Hold” and an average target price of $25.00.

Eikon Therapeutics Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.